Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
– NDA Resubmission Addresses Issues Related to Vial Compatibility – – If Approved, Lenacapavir Would be the First and the Only HIV-1 Treatment Option Administered Twice-Yearly – FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, … [Read more…]
